ACRV FDA Grants Fast Track Designation For Development Of ACR-368 In Platinum-Resistant Ovarian Cancer And Endometrial Cancer$Acrivon Therapeutics(ACRV)$
| 发布于: | Android | 转发：0 | 回复：0 | 喜欢：0 |
ACRV FDA Grants Fast Track Designation For Development Of ACR-368 In Platinum-Resistant Ovarian Cancer And Endometrial Cancer$Acrivon Therapeutics(ACRV)$